Pfizer drops Xeljanz patent suits
Molly Woodward / Shutterstock.com
The long-running legal saga between the pharma giant and the NHS as well as generic drug makers has developed further, as Darren Smyth of EIP explains.
On February 1 2023, the Court of Appeal of England and Wales handed down its decision in the latest instalment of the ongoing litigation concerning Pfizer’s product Lyrica (pregabalin), which first emerged back in 2014.
This decision leaves NHS Scotland open to continue to push for damages from Pfizer, although most NHS trusts have now settled their claims.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
EIP, Pfizer, pregabalin, litigation, NHS, generic drug makers, Court of Appeal of England and Wales, infringement, injunction, Allergan, Dr Reddys, Mylan